Ból jako działanie niepożądane : dolegliwości bólowe w trakcie farmakoterapii wybranymi grupami leków

• Autorzy: Baranowski J. , Klęczar K. , Białecka M.

Warianty tytułu

EN

Pain as a side effect : pain in result of pharmacotherapy with chosen drug groups

• Języki publikacji: PL

Abstrakty

PL

Wstęp i cel pracy: Farmakoterapia jest podstawą dzisiejszej medycyny. Wszystkie grupy leków obarczone są jednak ryzykiem wystąpienia działań niepożądanych. Celem niniejszej pracy jest przedstawienie dolegliwości bólowych u pacjentów, wyindukowanych często stosowanymi grupami leków. Materiał i metody: Na podstawie dostępnego piśmiennictwa wskazano grupy leków, które mogą powodować działania niepożądane w postaci bólu. Ponadto podjęto próbę opisania patomechanizmu, występujących objawów klinicznych oraz możliwości terapeutycznych. Wyniki: Nadużywanie wszystkich leków przeciwbólowych i terapia nitratami często prowadzi do polekowych bólów głowy. Opioidy mogą indukować różnorodne dolegliwości bólowe, w mechanizmach: hiperalgezji indukowanej opioidami, tolerancji na opioidy, allodynii oraz bólu z odstawienia. Zarówno statyny jak i chinolony wywołują dolegliwości bólowe z układu ruchu. Chemioterapia jest przyczyną neuropatii obwodowej. Wnioski: Każda grupa leków jest obarczona działaniami niepożądanymi, które należy zgłaszać do stosownej instytucji.

EN

Introduction and aim: Pharmacotherapy is the core of modern medicine. Unfortunately all drugs may lead to side effects. The aim of this paper is to present the appearance of pain among patients undergoing a treatment with commonly used medications. Materials and methods: On the grounds of the available literature, the authors identify several drug groups that can cause pain. Moreover, pathomechanisms as well as clinical symptoms and possible therapies were described. Results: Headaches may be caused by a medication-overuse in the therapy with analgesics and nitrates. Opioids are known to induce pain in various mechanisms: opioid-induced hyperalgesia, tolerance, allodynia and withdrawal. Both statins and quinolones may lead to muscle ache. Peripheral neuropathy is a result of chemotherapy. Conclusion: None of the investigated drugs are free from side effects. The occurrence of such phenomena must be reported to the adequate institution.

Słowa kluczowe

PL

ból polekowy; hiperalgezja indukowana opioidami; ból głowy; leki przeciwbólowe; nadużywanie leków przeciwbólowych; nitraty; ból mięśni; statyny; chinolon; neuropatia obwodowa wyindukowana chemioterapią

EN

drug related pain; medication overuse headache; opioid induced hyperalgesia; nitrates; myopathy; statins; quinolones; chemotherapy induced peripheral neuropathy

• Wydawca: Wyższa Szkoła Techniczno-Ekonomiczna w Szczecinie
• Czasopismo: Problemy Nauk Stosowanych
• Rocznik: 2017
• Tom: T. 6
• Strony: 107--118
• Opis fizyczny: Bibliogr. 66 poz.

Twórcy

autor

Baranowski J.

• Pomorski Uniwersytet Medyczny w Szczecinie, Studenckie Koło Naukowe przy Katedrze Farmakologii

autor

Klęczar K.

• Pomorski Uniwersytet Medyczny w Szczecinie, Studenckie Koło Naukowe przy Katedrze Farmakologii

autor

Białecka M.

• Pomorski Uniwersytet Medyczny w Szczecinie, Katedra Farmakologii, Zakład Farmakokinetyki i Terapii Monitorowanej

Bibliografia

• [1] Kurita G.P., Pimenta C.A.: Compliance with chronic pain treatment: study of demographic, therapeutic and psychosocial variables. Arq Neuropsiquiatr. (2003), 61(2B): 416-25.
• [2] Westergaard M.L., Glümer C., Hansen E.H., Jensen R.H.: Medication overuse, healthy lifestyle behaviour and stress in chronic headache: Results from a population-based representative survey. Cephalalgia. (2016), 36(1): 15-28.
• [3] Sinclair A.J., Sturrock A., Davies B., Matharu M.: Headache management: pharmacological approaches. Practical Neurology. (2015), 15(6): 411-423.
• [4] Munksgaard SB., Jensen R.H.: Medication overuse headache. Headache. (2014), 54(7): 1251-1257.
• [5] Srikiatkhachorn A., le Grand S.M., Supornsilpchai W., Storer R.J.: Pathophysiology of medication overuse headache - an update. Headache. (2014), 54(1): 204-210.
• [6] Westergaard M.L., Hansen E.H., Glümer C., Jensen R.H.: Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse. Eur J Clin Pharmacol. (2015), 71(7): 851-860.
• [7] Chiang C.C., Schwedt T.J., Wang S.J., Dodick D.W.: Treatment of medication-overuse headache: A systematic review. Cephalalgia. (2016), 36(4): 371-386.
• [8] Lucchesi C., Baldacci F., Cafalli M., Chico L., Lo Gerfo A., Bonuccelli U., Siciliano G., Gori S.: Evidences of reduced antioxidant activity in patients with chronic migraine and medication-overuse headache. Headache. (2015), 55(7): 984-991.
• [9] Westergaard M.L., Hansen E.H., Glümer C., Olesen J., Jensen R.H.: Definitions of medication- overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. (2014), 34(6): 409-425.
• [10] Evers S., Jensen R.; European Federation of Neurological Societies.: Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol. (2011), 18(9): 1115-1121.
• [11] Taghdiri F., Togha M., Razeghi Jahromi S., Paknejad S.M.: Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. (2015), 55(1): 128-135.
• [12] Weatherall M.W., Telzerow A.J., Cittadini E., Kaube H., Goadsby P.J.: Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology. (2010), 75(12): 1098-1103.
• [13] Mendelson J., Flower K., Pletcher M.J., Galloway GP.: Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp Clin Psychopharmacol. (2008), 16 (5): 435-441.
• [14] Tompkins D.A., Campbell C.M.: Opioid-induced hyperalgesia: Clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. (2011), 15(2): 129-136.
• [15] Shy M.E., Frohman E.M.: Quantitative sensory testing. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology (2003), 60(6), 898-904.
• [16] Célèrier E., Laulin J.P., Corcuff .JB., Le Moal M., Simonnet G.: Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci., (2001), 21(11), 74-80.
• [17] Vorobeychik Y., Chen L., Bush M.C., Mao J.: Improved opioid analgesic effect following opioid dose reduction. Pain Med., (2008), 9(6), 724-727.
• [18] Yi-Lin Zhao, Shao-Rui Chen, Hong Chen, Hui-Lin Pan: Chronic opioid potentiates presynaptic but impairs postsynaptic N-Methyl-d-aspartic acid receptor activity in spinal cords. Implications for opioid hyperalgesia and tolerance. J Biol Chem. (2012), 287(30), 25073-25085.
• [19] Compton P., Kehoe P., Sinha K., Torrington M.A., Ling W.: Gabapentin improves coldpressor pain responses in methadone-maintained patients. Drug Alcohol Depend. (2010), 109(1-3), 213-219.
• [20] Middleton C., Harden J.: Acquired pharmaco-dynamic opioid tolerance: a concept analysis. J Adv Nurs. (2014), 70(2), 272-281.
• [21] Cleophas T.J., Niemeyer M.C., van der Wall E.E., van der Meulen J.: Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group. Angiology. (1996), 47(7): 679-685.
• [22] Bagdy G., Riba P., Kecskeméti V., Chase D., Juhász G.: Headache-type adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol. (2010), 160(1): 20-35.
• [23] Christiansen I., Iversen H.K., Olesen J.: Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia. (2000), 20(5): 437-444.
• [24] Juhasz G., Zsombok T., Modos E.A., Olajos S., Jakab B., Nemeth J., Szolcsanyi J., Vitrai J., Bagdy G.: NO-induced migraine attack: strong increase in plasma calcitonin generelated peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. (2003), 106(3): 461-470.
• [25] Ahern G.P., Klyachko V.A., Jackson M.B.: cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci. (2002), 25(10): 510-517.
• [26] Kuzawińska O., Lis K., Cessak G., Bałkowiec-Iskra E.: Znaczenie CGRP w patogenezie i leczeniu migreny. Farmakoter Psychiatr Neurol. (2015), 31(2): 127-140.
• [27] Becker W.J.: Acute Migraine Treatment in Adults. Headache. (2015), 55(6): 778-793.
• [28] Dodick D., Lipton R.B., Martin V., Papademetriou V., Rosamond W., Maassen van Den-Brink A., Loutfi H., Welch K.M., Goadsby P.J., Hahn S., Hutchinson S., Matchar D., Silberstein S., Smith T.R., Purdy R.A., Saiers J.; Triptan Cardiovascular Safety Expert Panel.: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. (2004), 44(5): 414-425.
• [29] Thadani U., Rodgers T.: Side effects of using nitrates to treat angina. Expert opin drug saf. (2006), 5(5): 667-674.
• [30] Evers S., Afra J., Frese A., Goadsby P.J., Linde M., May A., Sándor P.S.: EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol. (2006), 13(6): 560-572.
• [31] Evers S., Afra J., Frese A., Goadsby P.J., Linde M., May A., Sándor P.S.: EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. (2009), 16: 968-981.
• [32] Evans M., Rees A.: Effects of HMG-CoA reductase inhibitors on skeletal muscle. Drug-Safety. (2002) 25: 649.
• [33] Tiwari A., Bansal V., Chugh A., Mookthiar K.: Statins and myotoxicity: a therapeutic limitation. Expert Opinion on Drug Safety. (2006), 5, 651-666.
• [34] Thompson P.D., Clarkson P., Karas R.H.: Statin-associated myopathy. JAMA. (2003), (13), 1681-1690.
• [35] Ucar M., Mjorndal T., Dahlqist R.: HMG-CoA reductase inhibitors and myotoxicity. Drug Safety. (2000), 22 (6), 441-457.
• [36] Thompson P.D., Clarkson P., Karas R.H.: Statin-associated myopathy. JAMA, (2003), 289, (13), 1681-1690.
• [37] Brown M.S.: Coenzyme Q10 with HMG-CoA reductase inhibitors. USA patent, (1990).
• [38] Sathasivam S.: Statin Induced myotoxicity. Eur J intern Med. (2012), 23, (4), 317-324.
• [39] Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. (2010), 41(2), 185-190.
• [40] Pasternak R.C., Smith Jr S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C.: Clinical advisory on the use and safety of statins. Stroke (2002), 33, 2337-2341.
• [41] Rosenson R.S.: Current overview of statin-induced myopathy. Am J Med 2004;116: 408-416.
• [42] Davidson M.H., Robinson J.G.: Safety of aggressive lipid management. J Am Coll Cardiol (2007), 49, 1753-1762.
• [43] Bottorff M. Statin safety and drug interactions: clinical implications. Am J Cardiol. (2006), 97, 27-31.
• [44] Mutschler E., Geisslinger G., Kroemer H.K., Ruth P., Schafer-Korting M.: Kompendium farmakologii i toksykologii Mutschlera. Stuttgart, (2005), 39-48.
• [45] Yildrim P.: Association patterns in open data to explore ciprofloxacin adverse events. Appl Clin Inform. (2015), 6(4), 728-747.
• [46] Kim G.K.: The risk of fluoroquinolone-induced tendinopathy and tendon rupture: What does the clinician need to know? J Clin Aesthet Dermatol. (2010), 3(4), 49-54.
• [47] WHO Pharmmaceuticals Newsletter. (2003), 1.
• [48] Corrao G., Zambon A., Bertù L., Mauri A., Paleari V., Rossi C., Venegoni M.: Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Safety. 2006, 29(10), 889-896.
• [49] Williams R.J., Attia E., Wickiewicz T.L., Hannafin J.A.: The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med. (2000), 28(3), 364-369.
• [50] Damuth E., Heidelbaugh J., Malani P.N., Cinti S.K.: An elderly patient with fluoroquinolone-associated achilles tendinitis. Am J Geriatr Pharmacother. (2008), 6(5), 264-268.
• [51] Boyle P., Levin B.: World Cancer Report. International Agency for Research on Cancer. (2008).
• [52] Brewer J.R., Morrison G., Dolan M.E., Fleming G.F.: Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecologic oncology. (2016), 140(1): 176-183.
• [53] Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C.: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. (2008), 44(11): 1507-1515.
• [54] Park S.B., Goldstein D., Krishnan A.V., Lin C.S., Friedlander M.L., Cassidy J., Koltzenburg M., Kiernan MC.: Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. (2013), 63(6): 419-437.
• [55] Ezendam N.P., Pijlman B., Bhugwandass C., Pruijt J.F., Mols F., Vos M.C., Pijnenborg JM., van de Poll-Franse LV.: Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. (2014), 135(3): 510-517.
• [56] Hausheer F.H., Schilsky R.L., Bain S., Berghorn E.J., Lieberman F.: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. (2006), 33(1): 15-49.
• [57] Wang X.M., Lehky T.J., Brell J.M., Dorsey S.G.: Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. (2012), 59(1): 3-9.
• [58] Areti A., Yerra V.G., Naidu V., Kumar A.: Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy. Redox Biology. (2014), 2: 289-295.
• [59] Smith E.M.L., Pang H., Cirrincione C., et al.: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. (2013), 309(13): 1359-1367.
• [60] Kim J.H., Dougherty P.M., Abdi S.: Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. Gynecol Oncol. (2015), 136(3): 453-459.
• [61] Cioroiu C., Weimer L.H.: Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. (2017), 17(6): 47.
• [62] Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D.: Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: A Comprehensive literature review. Front Pharmacol. (2017); 8: 86.
• [63] Ali A.K.: Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol. (2014), 24(4), 279-285.
• [64] Tome A.M., Filipe A.: Quinolones, review of psychiatric and neurological adverse reactions. Drug Saf. (2011), 34(6), 465-488.
• [65] Watemberg N., Matar M., Har-Gil M., Mahanajah M.: The influence of excessive chewing gum use on headache frequency and severity among adolescents. Pediatric Neurology, (2014), 50 (1), 69-72.
• [66] Yi P., Przybylkowski P.: Opioid induced hyperalgesia. Pain Med, (2015), 16, 32-36.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).